Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by bringon10baggeron Oct 19, 2019 4:53pm

183 Views

Post# 30247756

RE:RE:RE:RE:3 catalysts to push SP higher

Could see .50 on Monday......MacWirther on BNN Monday and he has spoke favourably each time he's been on in last 6 months and I'm sure again on Monday, could near .50 mark or higher Monday.......

Mott67 wrote: I mostly agree but I think that it might go a bit more like this:

build up to inevitable NR for final patient enrolled: 55-65 cents
final patient announced: 70 -80 cents
build up to results: 90 -99 cents
positive results: $1.25 - 1.60
partner announcement: $3-5